4 research outputs found

    Oxidation of an Azo-Dye via the Photo-Fenton Process under Heterogeneous and Homogeneous Conditions

    No full text
    In today’s industries, a diversity of processes give rise to increasing numbers of non-biodegradable compounds that need to be degraded totally or transformed to other less toxic and/or more biodegradable compounds, before their discharge into the environment. One such compound chosen for this study is Orange II, a representative azo-dye that is widely used and easy to monitor in its degradation. The photo-Fenton process was used under heterogeneous and homogeneous conditions to study several different variables. At the end of this research, a comparative study was carried out between the two types of catalysis. It was observed that better results in primary degradation and mineralization were provided by homogeneous catalysis. The photo-Fenton process takes place effectively under heterogeneous and homogeneous catalysis conditions. The process is much faster under homogeneous conditions than under heterogeneous conditions (99.9 and 24% after 90 min, respectively, especially when only 2 ppm of iron in solution is required). Mineralization was observed through total organic carbon, through the variable C/Co as a function of time during photo-Fenton and Orange II degradation, and the data obtained for the final oxidation capacity are in agreement with the experimental percentages of mineralization. A linear fit was observed using the Chan–Chu kinetic model for heterogeneous and homogeneous catalysis. For heterogeneous catalysis, 56% mineralization was reached whereas the model predicts 63%. Regarding homogeneous catalysis, according to the model, 100% mineralization is reached because (1/σ) takes a value greater than 1 since the model calculates it on infinite time

    Outcomes after perioperative SARS-CoV-2 infection in patients with proximal femoral fractures: an international cohort study

    Get PDF
    Objectives Studies have demonstrated high rates of mortality in people with proximal femoral fracture and SARS-CoV-2, but there is limited published data on the factors that influence mortality for clinicians to make informed treatment decisions. This study aims to report the 30-day mortality associated with perioperative infection of patients undergoing surgery for proximal femoral fractures and to examine the factors that influence mortality in a multivariate analysis. Setting Prospective, international, multicentre, observational cohort study. Participants Patients undergoing any operation for a proximal femoral fracture from 1 February to 30 April 2020 and with perioperative SARS-CoV-2 infection (either 7 days prior or 30-day postoperative). Primary outcome 30-day mortality. Multivariate modelling was performed to identify factors associated with 30-day mortality. Results This study reports included 1063 patients from 174 hospitals in 19 countries. Overall 30-day mortality was 29.4% (313/1063). In an adjusted model, 30-day mortality was associated with male gender (OR 2.29, 95% CI 1.68 to 3.13, p80 years (OR 1.60, 95% CI 1.1 to 2.31, p=0.013), preoperative diagnosis of dementia (OR 1.57, 95% CI 1.15 to 2.16, p=0.005), kidney disease (OR 1.73, 95% CI 1.18 to 2.55, p=0.005) and congestive heart failure (OR 1.62, 95% CI 1.06 to 2.48, p=0.025). Mortality at 30 days was lower in patients with a preoperative diagnosis of SARS-CoV-2 (OR 0.6, 95% CI 0.6 (0.42 to 0.85), p=0.004). There was no difference in mortality in patients with an increase to delay in surgery (p=0.220) or type of anaesthetic given (p=0.787). Conclusions Patients undergoing surgery for a proximal femoral fracture with a perioperative infection of SARS-CoV-2 have a high rate of mortality. This study would support the need for providing these patients with individualised medical and anaesthetic care, including medical optimisation before theatre. Careful preoperative counselling is needed for those with a proximal femoral fracture and SARS-CoV-2, especially those in the highest risk groups. Trial registration number NCT0432364
    corecore